Use of escin

Abstract

The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.

1 .- 12 . (canceled) 
   
   
       13 . A method of treating diseases mediated or caused by activated granulocytes comprising:
 obtaining a pharmaceutical preparation comprising escin; and   administering the preparation to a subject;   
     wherein a disease mediated or caused by activated granulocytes is treated in the subject. 
   
   
       14 . The method of  claim 13 , wherein the escin is beta-escin. 
   
   
       15 . The method of  claim 13 , wherein the granulocytes are hyperactivated. 
   
   
       16 . The method  claim 13 , wherein the disease is an allergy or a secondary disease of an allergy. 
   
   
       17 . The method of  claim 13 , wherein the disease is a type I or type III allergy or septic shock. 
   
   
       18 . The method of  claim 17 , wherein the disease is a type I allergy. 
   
   
       19 . The method of  claim 13 , wherein the disease is allergic rhinitis, Urticaria pigmentosa, atopic dermatitis, allergic asthma, food allergy, allergic conjunctivitis, allergy of the intestinal tract, an allergy of the ears, psoriasis, arthritis, immune thrombocytopenia, autoimmune hemolytic anemia, systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, or multiple sclerosis 
   
   
       20 . The method of  claim 13 , wherein the granulocytes are eosinophils, neutrophils, basophils, and/or mast cells. 
   
   
       21 . The method of  claim 13 , wherein the preparation is in form of a preparation for topical or mucosal use. 
   
   
       22 . The method of  claim 21 , wherein the preparation is a skin lotion, cream, powder, spray or gargle solution. 
   
   
       23 . The method of  claim 13 , wherein the preparation is in form for oral intake. 
   
   
       24 . The method of  claim 23 , wherein the preparation is a pastille, tablet, gum, lozenge, powder, or drinking solution. 
   
   
       25 . The method of  claim 13 , wherein the preparation further comprises a carrier, excipient, or additive. 
   
   
       26 . The method of  claim 25 , wherein the preparation further comprises a polymeric excipient. 
   
   
       27 . The method of  claim 13 , wherein the escin is administered in a dose of from 0.01 mg/kg to 500 mg/kg. 
   
   
       28 . The method of  claim 27 , wherein the escin is administered in a dose of from 0.1 mg/kg to 100 mg/kg. 
   
   
       29 . The method of  claim 28 , wherein the escin is administered in a dose of from 1 mg/kg to 40 mg/kg. 
   
   
       30 . The method of  claim 13 , wherein the subject is a human.